Document:

Exhibit 10.5

 

Confidential

 

Consultant
Services Agreement

 

This Agreement
(this “Agreement”), effective as January 1, 2014 (the “Effective Date”) sets forth the terms
and conditions whereby Vinay Jain, M.D. (“Consultant”) will provide certain services for AROG Pharmaceuticals
, Inc. (“AROG”). Consultant and AROG are referred each individually referred to herein as a “Party”
and collectively as the “Parties.”

 

		1.	Services.
                                         Consultant agrees to provide services consistent with Consult ant’ s duties
                                         and responsibilities as AROG’s Chief Executive Officer (“Services”).
                                         Consultant agrees to devote its best efforts to perform the Services promptly and diligently.

 

		2.	Compensation.
                                         In consideration of the Services to be provided by Consultant pursuant to this Agreement,
                                         AROG shall pay Consultant a monthly fee of Twelve Thousand Five Hundred Dollars ($12,500)
                                         (or One Hundred Fifty Thousand Dollars ($150,000) if annualized).

 

		3.	Confidential
                                         Information. “Confidential Information” means any and all information,
                                         and copies or reproductions thereof, whether in written, graphic or oral form, whether
                                         or not such information is identified as “confidential” at the time
                                         of dis closure, that is provided to Consultant by AROG, an affiliate of AROG, or on behalf
                                         of AROG, either directly or indirectly, or is acquired by Consultant or observed or generated
                                         in connection with the Consultant’s performance or anticipation of performance
                                         of Services to AROG or an affiliate of AROG.

 

		4.	Non-disclosure,
                                         Non-use and Exceptions.

 

		(a)	Non-disclosure
                                         and Non-use of Confidential Information. Consultant shall hold in strict confidence
                                         and shall not disclose, deliver or disseminate any Confidential Information to third
                                         parties that are not affiliates of AROG. Consultant shall use the Confidential Information
                                         in accordance with the obligations herein and solely for providing Services pursuant
                                         to the Agreement, and shall not use, copy, disclose or exploit such Confidential Information
                                         for Consultant’s own benefit or for the benefit of another unless expressly permitted
                                         herein or with AROG ‘s prior written consent. Consultant acknowledges that it may
                                         receive material, non-public information about AROG and its business. Consultant also
                                         acknowledges that it may receive confidential or proprietary information of AROG ‘s
                                         affiliates. Consultant agrees that such Confidential Information of AROG’ s affiliates
                                         is subject to the terms hereof and shall be used only as necessary to provide Services.

 

		(b)	Exceptions.
                                         The obligations of confidentiality specified in Section 3(a) above shall not apply
                                         with respect to any Confidential Information solely to the extent that such Confidential
                                         Information:

 

		(i)	is
                                         or becomes publicly known through no breach of this Agreement or any other wrongful act
                                         of Consultant;

 

		(ii)	is
                                         disclosed without restriction on further disclosure or use to Consultant by a third party
                                         having the legal right to disclose such information; or

 

		(iii)	has
                                         been independently developed by Consultant without reference to or reliance upon Confidential
                                         Information or other AROG proprietary information as can be shown by contemporaneous
                                         written documents.

 

    
Jain.AROG Consulting Agreement
 January 2014
 Page 1 of 3
 

    Confidential

    

 

If
Consultant is required to disclose Confidential Information by law or legal process, Consultant shall safeguard the Confidential
Information to the extent allowed by law and promptly provide AROG appropriate prior written notice.

 

		5.	No
                                         Implied Rights. Nothing herein shall be construed as granting any right or license
                                         to Consultant of AROG’s intellectual property. This Agreement implies no obligation
                                         on either Party to enter into any further agreement with the other. Notwithstanding any
                                         terms to the contrary herein, should AROG and Consultant enter into a business relationship
                                         without the benefit of an agreement that supersedes this Agreement, the terms of this
                                         Agreement shall continue to govern disclosures of Confidential Information. Such business
                                         relationship shall. be deemed to be part of the “Services” hereunder
                                         and the Term hereof shall be extended until such relationship terminates or expires.

 

		6.	Term.
                                         This Agreement (the “Term”) shall begin on the Effective Date
                                         and continue until terminated.

 

		7.	Miscellaneous.
                                         

 

		(a)	This
                                         Agreement sets forth the entire agreement and understanding between the Parties and supersedes
                                         all prior oral and written agreements and understandings between them relating to the
                                         subject matter of this Agreement. This Agreement may not be modified in whole or part,
                                         except by a writing signed by both Parties. This Agreement may not be assigned or otherwise
                                         transferred by Consultant without AROG’ s prior written consent.

 

		(b)	AROG
                                         or Consultant may terminate this agreement at any time.

 

		(c)	At
                                         AROG’s request and direction or upon termination of the Agreement, Consultant shall
                                         return or destroy the Confidential Information or any document or information based on
                                         or embodying Confidential Information received or generated by Consultant. If Confidential
                                         Information is destroyed, Consultant shall promptly send written confirmation of its
                                         destruction; provided, however, that Consultant may retain one (1) copy of Confidential
                                         Information in a secure location for the sole purpose of monitoring its compliance with
                                         this Agreement, laws and regulations.

 

		(d)	This
                                         Agreement may be amended only by a written instrument signed by the Parties hereto. No
                                         waiver of any provision of this Agreement by AROG in any manner shall be deemed to be
                                         or construed as a further or continuing waiver or stopped of any such provision or of
                                         any other provision of the Agreement. If any provision of this Agreement shall. be found
                                         to be unenforceable in any respect, the validity and enforceability of the remaining
                                         provisions shall not in any way be affected or impaired, provided the surviving agreement
                                         materially comports with the Parties ‘ original intent. This Agreement shall be
                                         governed by and interpreted in accordance with the laws of the state of Texas, without
                                         regard to its choice of law provisions.

 

		(e)	The
                                         provisions of this Agreement are necessary for the protection of AROG’s business
                                         and goodwill and are considered by the Parties to be reasonable for such purpose. Consultant
                                         agrees that any breach of this Agreement may cause AROG substantial and irreparable harm
                                         and, therefore, in the event of any such breach, in addition to other remedies that may
                                         be available to AROG, AROG shall have the right to seek specific performance and other
                                         injunctive and equitable relief.

 

    
Jain.AROG Consulting Agreement
 January 2014
 Page 2 of 3
 

    Confidential

    

 

		(f)	This
                                         Agreement may be executed in counterparts, each of which shall be an original, but all
                                         of which together shall constitute one and the same agreement.

 

		(g)	Any
                                         communications hereunder shall be addressed to the other Party at the address provided
                                         above and to the attention of the signatory below.

 

IN WITNESS
WHEREOF, Consultant accepts the terms of this Agreement as of the Effective Date.

 

	VINAY JAIN, M.D.	 
	 	 
	 	 
	By:	/s/ Vinay Jain, M.D.	 
	 	Vinay Jain, M.D.	 

 

 

 

    
Jain.AROG Consulting Agreement
 January 2014
 Page 3 of 3Exhibit 10.10

 

 

ASSET
PURCHASE AGREEMENT

 

This
Asset Purchase Agreement (this “Agreement”) is made and entered into effective as of January 5, 2015 (the “Effective
Date”), by and between Arog Pharmaceuticals, Inc., a Delaware corporation (“Seller”), and Videra
Pharmaceuticals, LLC a Delaware limited liability company (“Buyer”). Seller and Buyer are sometimes referred
to herein as the “Parties,” and each, a “Party.”

 

RECITALS

 

WHEREAS,
Seller desires to contribute, transfer, assign, convey, set over, grant sell and deliver (collectively, “Transfer”)
to Buyer the assets identified on Exhibit A attached hereto (the “Purchased Assets”) free and clear
of all Liens other than Permitted Liens; and

 

WHEREAS,
the aggregate consideration for the Purchased Assets shall be One Hundred Twenty Five Thousand Dollars ($125,000) (the “Purchase
Price”) and Buyer’s assumption of certain liabilities of Seller identified on Exhibit B attached hereto
(the “Assumed Liabilities”).

 

NOW,
THEREFORE, in consideration of the mutual agreements set forth herein, and subject to the terms and provisions set forth below,
the Parties hereto agree as follows:

 

AGREEMENT

 

1.            
Defined Terms. For purposes of this Agreement, the terms defined in this Section 1
shall have the meanings herein specified unless the context otherwise requires.

 

1.1           “Contract” means any written or oral legally binding contract, agreement,
instrument, commitment or undertaking of any nature.

 

1.2           “Excluded Assets” means any assets of Seller that are not Purchased Assets.

 

1.3           “Governmental Entity” means any: (a) nation, state, county, city, district
or other similar jurisdiction of any nature; (b) federal, state, local or foreign government; (c) governmental or quasi-governmental
authority of any nature (including any governmental agency, branch, commission, bureau, instrumentality, department, official,
entity, court or tribunal); (d) multinational organization or body; or (e) body or other Person entitled by applicable Law, contract
or other arrangement to exercise any arbitrative, administrative, certification, executive, judicial, legislative, licensing,
police, regulatory or taxing authority or power.

 

1.4           “Law” means any applicable provision of any constitution, treaty, statute,
law (including the common law), rule, regulation, ordinance, code or order enacted, adopted, issued or promulgated by any Governmental
Entity.

 

1.5           “Liability” means any liability or obligation of any kind or nature (whether
known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, or due or
to become due).

 

     

     

    

 

1.6           “Lien” means any mortgage, claim, pledge, security interest, charge, lien,
option or other right to purchase, restriction or reservation or any other encumbrance whatsoever.

 

1.7           “Material Adverse Effect” means, with respect to any Person, any incident,
condition, change, effect or circumstance that, individually or when taken together with all such incidents, conditions, changes,
effects or circumstances in the aggregate, has had or would reasonably be expected to have a material adverse effect on the business,
operations, condition (financial or otherwise), properties, Liabilities, results of operations or prospects of such Person and
its subsidiaries, taken as a whole or any of them taken individually.

 

1.8           “Permitted Lien” means any: (a) Lien for any tax, assessment or other
governmental charge that is not yet due and payable or that may thereafter be paid without penalty; or (b) mechanic’s, materialmen’s,
landlord’s or similar Lien arising or incurred in the ordinary course of business of the applicable Person that secures
any amount that is not overdue; or (c) any license to intellectual property rights.

 

1.9           “Person” means any individual, partnership, corporation, limited liability
company, association, joint stock company, trust, joint venture, unincorporated organization or any other business entity or association
or any Governmental Entity.

 

2.           
Transfer of Assets; Assumption of Liabilities: Issuance of Shares. The closing (the
“Closing”) of the transactions contemplated by this Agreement (the “Asset Sale”) shall be
consummated effective as of 12:01 a.m. Central Time on the Effective Date. At the Closing, (i) Seller shall Transfer the Purchased
Assets to Buyer, free and clear of all Liens other than Permitted Liens, and (ii) Buyer shall assume the Assumed Liabilities and
pay to Seller the Purchase Price via wire transfer of immediately available funds to an account designated by Seller. In connection
with the Asset Sale, at the Closing, Seller and Buyer shall enter into (A) an Assignment and Assumption Agreement and Bill of
Sale substantially in the form attached hereto as Exhibit C, (B) a Patent Assignment substantially in the form attached hereto
as Exhibit D and (B) a License Agreement substantially in the form attached hereto as Exhibit E. The Parties acknowledge that
no consideration, other than as specifically recited herein, is or will be received by Seller in exchange for the Transfer of
the Purchased Assets set forth herein. Notwithstanding any other provision of this Agreement, Buyer shall not assume any Liabilities
of Seller nor any affiliate of Seller other than the Assumed Liabilities.

 

3.           
Representations and Warranties.

 

3.1           Representations and Warranties of Seller. Seller represents and warrants to Buyer
as of the Effective Date as follows:

 

(a)              
Organization and Standing. Seller is a corporation duly organized and validly existing
under the Laws of the State of Delaware. Seller has the requisite corporate power and authority to own the Purchased Assets and
to conduct its business as now being conducted, and is duly qualified to do business and is in good standing in each jurisdiction
in which the ownership or leasing of its properties or assets or the conduct of its business requires such qualification, except
where the failure to be so qualified or in good standing has not had and would not reasonably be expected to have a Material Adverse
Effect on Seller.

 

     

     

    

 

(b)              
Authority . Seller has the requisite company power and authority to execute and deliver
and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution and delivery
of” this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of Seller. This Agreement has been duly executed and delivered by Seller and constitutes the legal,
valid and binding obligations of Seller, enforceable against Seller in accordance with its terms, except to the extent that enforceability
may be limited by the effect, if any, of any applicable bankruptcy, reorganization, insolvency, moratorium or other Laws affecting
the enforcement of creditors’ rights generally or any general principles of equity, regardless of whether such enforceability
is considered in a proceeding at law or in equity. Neither the execution and delivery by Seller of this Agreement nor the consummation
of the transactions contemplated hereby will conflict with or violate any provision of Seller’ s Certificate of Incorporation
or Bylaws, each as amended to date.

 

(c)              
Governmental Approvals. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with any Governmental Entity, is required on the part of Seller in connection
with the Transfer of the Purchased Assets to Seller and the other transactions contemplated by this Agreement and the other documents
contemplated hereby.

 

3.2           Representations and Warranties of Buyer. Buyer represents and warrants to Seller as
of the Effective Date as follows:

 

(a)              
Organization and Standing. Buyer is a limited liability company duly organized and
validly existing under the Laws of the State of Delaware. Buyer has the requisite company power and authority to own its assets
and properties and to carry on its business as now being conducted and is duly qualified to do business and is in good standing
in each jurisdiction in which the ownership or leasing of its properties or assets or the conduct of its business requires such
qualification, except where the failure to be so qualified or in good standing has not had and would not reasonably be expected
to have a Material Adverse Effect on Buyer.

 

(b)              
Authority. Buyer has the requisite company power and authority to execute and deliver
and perform its obligations under this Agreement and to consummate the transactions contemplated hereby. The execution and delivery
of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary corporate
action on the part of Buyer. This Agreement has been duly executed and delivered by Buyer and constitutes the legal, valid and
binding obligations of Buyer, enforceable against Buyer in accordance with its terms, except to the extent that enforceability
may be limited by the effect, if any, of any applicable bankruptcy, reorganization, insolvency, moratorium or other Laws affecting
the enforcement of creditors’ rights generally or any general principles of equity, regardless of whether such enforceability
is considered in a proceeding at law or in equity. Neither the execution and delivery by Buyer of this Agreement nor the consummation
of the transactions contemplated hereby will conflict with or violate any provision of Buyer’s Certificate of Formation
or Limited Liability Company Agreement, each as amended to date.

 

     

     

    

 

(c)              
Governmental Approvals. No consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any Governmental Entity is required on the part of Buyer in connection
with the receipt of the Purchased Assets, assumption of the Assumed Liabilities and the other transactions contemplated by this
Agreement and the other documents contemplated hereby.

 

3.3           The representations and warranties of Seller and the Buyer contained in Section 3
of this Agreement shall expire and be of no further force or effect as of the date that is twelve (12) months after the date of
the Closing.

 

4.            
Notices. All notices and other communications hereunder shall be in writing and shall
be deemed received (a) on the date of delivery if delivered personally or by messenger service, (b) on the date of confirmation
of receipt of transmission by facsimile (or, the first business day following such receipt if (i) the date is not a business day
or (ii) confirmation of receipt is given after 5:00 p.m., Pacific Time) or (c) on the date of confirmation of receipt if delivered
by a nationally recognized courier service (or, the first business day following such receipt if (i) the date is not a business
day or (ii) confirmation of receipt is given after 5:00 p.m., Pacific Time), to the Parties at the following address or facsimile
numbers (or at such other address or facsimile number for a Party as shall be specified by like notice):

 

if
to Seller, to:

Arog Pharmaceuticals, Inc.

Two Lincoln Centre

5420 LBJ Freeway, Suite 410

Dallas, Texas 75240

Fax: (469) 533-3966

Attention: CEO

 

if
to Buyer, to:

Videra Pharmaceuticals, LLC

Two Lincoln Centre

5420 LBJ Freeway, Suite 410

Dallas, Texas 75240

Fax: (214) 889-7070

Attention: CEO

 

5.           
Amendment. The Parties may cause this Agreement to be amended at any time by execution
of an instrument in writing signed on behalf of each of the Parties, except as otherwise required by Law.

 

6.           
Further Assurances. Each Party hereto shall, from time to time after the Closing,
at the request of any other Party hereto in writing and without further consideration, execute and deliver such other instruments
of conveyance, assignment, transfer and assumption, and take such other actions, as such other Party may reasonably request to
more effectively consummate the transactions contemplated by this Agreement.

 

     

     

    

 

7.           
Wrong Pocket. In the event that after the Closing, Seller or any of its affiliates
receives any payment related to any Purchased Asset, Seller agrees to use commercially reasonable efforts to remit any such payment
within five (5) business days (or cause to be remitted within five (5) business days) such funds to Buyer, but in any event such
funds shall be remitted to Buyer as soon as possible thereafter. In the event that Buyer or any of its affiliates receives any
payment related to any Excluded Assets after the Closing, Buyer agrees to use commercially reasonable efforts to remit any such
payment within five (5) business days (or cause to be remitted within five (5) business days) such funds to Seller, but in any
event such funds shall be remitted to Seller as soon as possible thereafter.

 

8.           
Assignment: Successors and Assigns. None of the rights and obligations of Seller or
Buyer may be assigned without the prior written consent of Buyer or Seller, respectively, and any purported assignment made without
such consent shall be void; provided, however, that the rights and obligations of a Party may be assigned and delegated
without the other Party’s consent (a) in connection with a transfer, merger, acquisition, reorganization or consolidation
of such Party, or with a sale of all or substantially all of such Party’ s assets, (b) to any affiliate of such Party, or
(c) to any successor Person who purchases the business of such Party. Subject to the foregoing, this Agreement (and the rights
and obligations hereunder) shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors
and permitted assigns (each of which successors and permitted assigns shall be deemed to be a Party hereto for all purposes of
this Agreement).

 

9.           
Waiver. Any Party may, to the extent legally allowed, (a) extend the time for the
performance of any of the obligations or other acts of the other Party, (b) waive any inaccuracies in the representations and
warranties made to such Party contained herein or in any document delivered pursuant hereto and (c) waive compliance with any
of the agreements or conditions for the benefit of such Party contained herein. Any such extension or waiver by any Party shall
not operate or be construed as a further or continuing extension or waiver. Any agreement on the part of a Party to any such extension
or waiver shall be valid only if set forth in an instrument in writing signed on behalf of such Party.

 

10.          
Severability. In the event that any provision of this Agreement, or the application
thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this
Agreement will continue in full force and effect and the application of such provision to other Persons or circumstances will
be interpreted so as reasonably to effect the intent of the Parties.

 

11.          
Governing Law. This Agreement and all disputes and controversies arising hereunder
shall be governed by and construed in accordance with the Laws of the State of Delaware without reference to such state’s
principles of conflicts of law.

 

12.         
Waiver of Jury Trial. EACH PARTY WAIVES ANY RIGHT TO TRIAL BY JURY IN ANY DISPUTE,
WHETHER SOUNDING IN CONTRACT, TORT, OR OTHERWISE, AMONG THE PARTIES ARISING OUT OF OR RELATED TO THE TRANSACTIONS CONTEMPLATED
HEREBY. ANY PARTY MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT
OF THE PARTIES TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

     

     

    

 

13.          
Attorneys’ Fees. Should any party institute any proceeding in court or otherwise
to enforce any provision hereof or for damages by reason of alleged breach of any provision of this Agreement, the prevailing
party shall be entitled to receive from the non-prevailing party such reasonable out-of-pocket expenses (including attorneys’
fees and expenses) incurred by the prevailing party in connection with any such proceeding.

 

14.          
Counterpart Execution. This Agreement may be executed in one or more counterparts,
all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been
signed by each of the Parties and delivered to the other Party, it being understood that all Parties need not sign the
same counterpart. The Parties may sign this Agreement in the original, by facsimile, by .PDF or by any other generally acceptable
electronic means.

 

15.          
Interpretation; Construction. In this Agreement: (a) the section headings are for
convenience of reference only and will not affect the meaning or interpretation of this Agreement; (b) the words “herein,”
“hereunder,” “hereby” and similar words refer to this Agreement as a whole (and not to the particular
sentence, paragraph or section where they appear); (c) terms used in the plural include the singular, and vice versa, unless the
context clearly requires otherwise; (d) unless expressly stated herein to the contrary, reference to any document means such document
as amended or modified and as in effect from time to time in accordance with the terms thereof; (e) unless expressly stated herein
to the contrary, reference to any applicable Law means such applicable Law as amended, modified, codified, replaced or reenacted,
in whole or in part, and as in effect from time to time, including any rule or regulation promulgated thereunder; (f) the words
“including,” “include” and variations thereof are deemed to be followed by the words “ without limitation;”
(g) “or” is used in the sense of “and/or;” “any” is used in the sense of “any or all;”
and “with respect to” any item includes the concept “of’ such item or “under” such item or
any similar relationship regarding such item; (h) unless expressly stated herein to the contrary, reference to a document, including
this Agreement, will be deemed to also refer to each annex, addendum, exhibit, schedule or other attachment thereto; (i) unless
expressly stated herein to the contrary, reference to a section, schedule or exhibit is to a section, schedule or exhibit, respectively,
of this Agreement; (j) when calculating a period of time, the day that is the initial reference day in calculating such period
will be excluded and, if the last day of such period is not a business day, such period will end on the next day that is a business
day; (k) with respect to all dates and time periods in or referred to in this Agreement, time is of the essence; and (l) the phrase
“the date hereof ‘ means the date of this Agreement, as stated in the first paragraph hereof.

 

[Remainder
of page intentionally Left blank]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the date first set forth above.

 

	 	AROG PHARMACEUTICALS, INC.
	 	 
	 	 
	 	By:	/s/ Vinay Jain
	 	 	Name:Vinay Jain, M.D.
	 	 	Title:CEO

 

 

	 	VIDERA PHARMACEUTICALS, LLC
	 	 
	 	 
	 	By:	/s/ Vinay Jain
	 	 	Name:Vinay Jain, M.D.
	 	 	Title:Manager

 

 

    	 

    	 

    

 

EXHIBIT
A

Purchased Assets

 

		1.	All
                                         of Seller’ s rights under the Contracts set forth on Schedule 1 hereto (collectively,
                                         the “Transferred Contracts”), including all claims, contract rights
                                         and warranty and product liability claims against third parties under the Transferred
                                         Contracts.

 

		2.	All
                                         Intellectual Property set forth on Schedule 2 and all rights of copyright in the
                                         tangible embodiments of the items identified below in Paragraphs 3 and 4
                                         that are primarily related to the Purchased Assets (collectively, the “Transferred
                                         IP”), and all rights to sue for or assert claims against and remedies against
                                         past, present or future infringement s or misappropriation of any or all of the Transferred
                                         IP, and rights of priority and protection of interests therein and to retain any and
                                         all amounts therefrom.

 

		3.	All
                                         data, records, files, manuals, blueprints and other documentation primarily related to
                                         the Purchased Assets, including: (i) service and warranty records; (ii) studies, reports,
                                         correspondence and other similar documents and records primarily related to the Purchased
                                         Assets, whether in electronic form or otherwise; and (iv) copies of all accounting and
                                         tax books, ledgers and records and other financial records primarily related to the Purchased
                                         Assets.

 

		4.	All
                                         policies and procedures, methods of delivery of services, disks, drawings and specifications,
                                         market studies, consultants’ reports and prototypes, primarily related to the Purchased
                                         Assets.

 

 

 

 

    	 

    	 

    

 

EXHIBIT
B

Assumed Liabilities

 

		1.	All
                                         Liabilities arising with respect to Buyer’ s use or exploitation of the Purchased
                                         Assets following the Closing, including all Liabilities arising under the Transferred
                                         Contracts following the Closing.

 

 

 

 

 

 

    	 

    	 

    

 

EXHIBIT
C

Assignment and Assumption Agreement and Bill of Sale

 

 

 

 

 

 

 

 

 

    	 

    	 

    

 

EXHIBIT
D

Patent Assignment Agreement

 

 

 

 

 

 

 

 

 

 

    	 

    	 

    

 

EXHIBIT
E

License Agreement

 

 

 

 

 

 

 

 

 

 

    	 

    	 

    

 

SCHEDULE
1

Transferred Contracts

 

		·	New
                                         York University School of Medicine - Material Transfer Agreement

 

		o	Effective
                                         April 1, 2014

 

		o	Tuberculosis

 

		o	PI:
                                         Joel D. Ernst

 

		o	Crenolanib
                                         Besylate

 

		·	Genon
                                         Biotechnologies, Ltd.

 

		o	Effective
                                         July 12, 2013

 

		o	JAK
                                         assays for selectivity

 

		o	PI:
                                         Olli Silvennoinen

 

		o	CP-637,451

 

    	 

    	 

    

 

SCHEDULE
2

Transferred IP

 

Patent Applications

 

		·	AROG:1003

 

		o	Application
                                         No. 14/447,139

 

		o	Method
                                         of Inhibiting FLT3 Kinase - CP-673451

 

Domain Name(s)

 

		·	Viderapharma.com

 

Know-how primarily related to
the Purchased Assets

 

 

 

 

 

    	 

    	 

    

 

SCHEDULE
3

 

Tangible
Assets

 

Compounds

 

	Compound Number (non-GMP Materials)	Salt
    Name	Total
    Milligrams (Approximate)	Lot#
	CP-673451	Base	1,052,800	041511-124-03
	CP-673451-01	Hydrochloride salt	5,300	047886-274-01
	CP-673451-10	Citrate salt	151	Various
    Lot Number(s)
	CP-673451-14	Acetate salt	16	Various
    Lot Number(s)
	CP-673451-15	P-Touluene sulphonate
    salt	3,700	Various
    Lot Number(s)
	CP-673451-24	Succinate salt	22	Various
    Lot Number(s)
	CP-673451-27	 	5	Various
    Lot Number(s)
	CP-673451-42	 	6	Various
    Lot Number(s)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]